KBY Biotech Indexv0.0.34
Search
← Pipeline|JNJ-179

JNJ-179

Approved
By Johnson & Johnson
Source: Trial-derived·Trials: 4
Modality
ADC
MOA
BETi
Target
KRASG12C
Pathway
Checkpoint
DMDSCLCNarcolepsy
Development Pipeline
Preclinical
~Jul 2009
→ ~Oct 2010
Phase 1
~Jan 2011
→ ~Apr 2012
Phase 2
~Jul 2012
→ ~Oct 2013
Phase 3
~Jan 2014
→ ~Apr 2015
NDA/BLA
~Jul 2015
→ ~Oct 2016
Approved
Jan 2017
→ Feb 2029
ApprovedCurrent
NCT08826703
1,349 pts·SCLC
2017-01→2027-05·Recruiting
NCT06416354
1,692 pts·Narcolepsy
2018-02→2027-11·Active
NCT06534231
1,619 pts·Narcolepsy
2025-12→2026-01·Not yet recruiting
+1 more trial
5,623 total pts3 indications
CompletedCurrentUpcoming
Catalysts (5)
2026-01-162mo agoPh3 Readout· Narcolepsy
2026-12-199mo awayOrphan Drug· DMD
2027-05-271.2y awayPh3 Readout· SCLC
2027-11-201.6y awayPh3 Readout· Narcolepsy
2029-02-192.9y awayPh3 Readout· DMD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Approved
Recruit…
Approved
Active
Approved
Recruit…
Approved
Not yet…
Catalysts
Ph3 Readout
2026-01-16 · 2mo ago
Narcolepsy
Orphan Drug
2026-12-19 · 9mo away
DMD
Ph3 Readout
2027-05-27 · 1.2y away
SCLC
Ph3 Readout
2027-11-20 · 1.6y away
Narcolepsy
Ph3 Readout
2029-02-19 · 2.9y away
DMD
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT08826703ApprovedSCLCRecruiting1349Mayo
NCT06416354ApprovedNarcolepsyActive1692PFS
NCT06534231ApprovedNarcolepsyNot yet recr...1619OS
NCT04486187ApprovedDMDRecruiting963DOR
Competitors (10)
DrugCompanyPhaseTargetMOA
LLY-1592Eli LillyNDA/BLAFGFRBETi
SovarapivirAbbViePhase 2/3IL-13BETi
BMY-4586Bristol-Myers SquibbPreclinicalKRASG12CIL-13i
DoxarapivirBristol-Myers SquibbPhase 3KRASG12CSOS1i
BAY-8733BayerPreclinicalAuroraABETi
AMG-4531AmgenPhase 2/3KRASG12CPRMT5i
REG-8074RegeneronPhase 2/3KRASG12CCAR-T BCMA
VRT-1891Vertex PharmaPhase 1KRASG12CPRMT5i
BII-1564BiogenPhase 2PSMABETi
SovanaritideArgenxPhase 3TNFαBETi